InflaRx Plans Two Phase 2 Izicopan Trials for 2027
InflaRx plans two Phase 2 studies of izicopan in ANCA-associated vasculitis in 2027.
Related stories
Optimus SBR Acquires Greenlight Consulting to Expand AI and Automation Capabilities
The acquisition is intended to expand capabilities for financial institutions, public sector organizations and healthcare.
M impact | EQUITY | Nov 03, 2026, 03:30 PM UTC
Oracle Said To Allocate 65% Of USD 10B Stock Sale To 10 Investors
L impact | EQUITY | Nov 03, 2026, 03:29 PM UTC
Mexico’s Main Stock Index Extends Gains Above 2%
M impact | EQUITY | Nov 03, 2026, 03:28 PM UTC
Sportradar Group Reports Third-Quarter Revenue of EUR362.5M
M impact | EQUITY | Nov 03, 2026, 03:28 PM UTC
BBVA Places CHF 290 Million Green Bond
BBVA placed CHF 290 million in a two-tranche senior preferred green bond issuance.
L impact | EQUITY | Nov 03, 2026, 03:28 PM UTC
NexPoint Residential Trust Reports Quarterly Results
NexPoint Residential Trust reported results for the quarter ended September 30.
M impact | EQUITY | Nov 03, 2026, 03:27 PM UTC